Clinical and experimental data proposed that Sharpin is down-regulated in AD tissues, and Sharpin-silencing could increase FLG expression in vitro, implicating Sharpin as a novel mediator in both inflammation responses and barrier repair (Tang et al., 2018). The gene discussed is FLG; the disease is Alzheimer disease.